Medpace Holdings Inc vs iShares Silver Trust — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while iShares Silver Trust trades at $53.17. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| MEDP | SLV | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | — |
52-Week High | $620.59 | $105.57 |
52-Week Low | $308.88 | $33.32 |
Enterprise Value | $14.55B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
SLV, the iShares Silver Trust ETF, trades at $50.98 with a slight 0.39% daily gain. The technical outlook is bearish, with moving averages signaling strong selling pressure and oscillators neutral. Recent news highlights silver's dual role as a monetary and industrial metal, with supply deficits and geopolitical tensions influencing prices. Financial ratios are not applicable as SLV is a commodity trust tracking silver prices, not a company with earnings.
The outlook for SLV hinges on silver's price trajectory, supported by industrial demand and supply constraints but pressured by Fed policy and dollar strength. Risks include volatility from macroeconomic shifts and competition from other silver ETFs like SIVR. Analyst sentiment is mixed, with silver's performance lagging gold year-to-date, yet long-term demand drivers remain intact.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →